Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Halberd Corp (HALB)

Halberd Corp (HALB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 4.45
  • Price/Book 16.90
Trade HALB with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0072 +8.33%
on 03/27/24
0.0092 -15.22%
on 04/05/24
+0.0006 (+8.33%)
since 03/26/24
3-Month
0.0060 +30.00%
on 02/13/24
0.0121 -35.54%
on 02/12/24
-0.0006 (-7.14%)
since 01/26/24
52-Week
0.0030 +160.00%
on 12/12/23
0.0122 -36.07%
on 09/18/23
-0.0042 (-35.00%)
since 04/26/23

Most Recent Stories

More News
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary

JACKSON CENTER, PA / ACCESSWIRE / July 20, 2022 / Halberd Corporation (OTC PINK:HALB) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd's patented extracorporeal...

HALB : 0.0078 (-3.70%)
Halberd's Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron

Boosts Effectiveness of Commercial Covid Antibodies by 45%

HALB : 0.0078 (-3.70%)
Halberd Corporation Update, CEO Letter and 2022 Expectations

Q2 Accomplishments and a Look to the Future

HALB : 0.0078 (-3.70%)
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

JACKSON CENTER, PA / ACCESSWIRE / June 21, 2022 / Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC PINK:HALB) announced the creation of...

HALB : 0.0078 (-3.70%)
Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification

JACKSON CENTER, PA / ACCESSWIRE / June 8, 2022 / Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next...

HALB : 0.0078 (-3.70%)
Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines

JACKSON CENTER, PA / ACCESSWIRE / May 24, 2022 / Halberd Corporation (OTC PINK:HALB) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted cytokine...

HALB : 0.0078 (-3.70%)
Halberd Engages Professional Firm to Proceed with FDA Filings

JACKSON CENTER, PA / ACCESSWIRE / May 18, 2022 / Halberd Corporation (OTC PINK:HALB) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug Administration's...

HALB : 0.0078 (-3.70%)
Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB

JACKSON CENTER, PA / ACCESSWIRE / May 12, 2022 / Halberd Corporation (OTC PINK:HALB) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step...

HALB : 0.0078 (-3.70%)
Dr. Gregg Sturrus' TEDx Talk(R) Features Halberd's Extracorporeal Treatment of Neurodegenerative Diseases

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

HALB : 0.0078 (-3.70%)
Halberd CEO Letter

Q1 Accomplishments and Q2 Plans JACKSON CENTER, PA / ACCESSWIRE / April 25, 2022 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK:HALB) This past quarter has witnessed some very significant...

HALB : 0.0078 (-3.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 0.0087
2nd Resistance Point 0.0084
1st Resistance Point 0.0083
Last Price 0.0078
1st Support Level 0.0079
2nd Support Level 0.0076
3rd Support Level 0.0075

See More

52-Week High 0.0122
Fibonacci 61.8% 0.0087
Last Price 0.0078
Fibonacci 50% 0.0076
Fibonacci 38.2% 0.0065
52-Week Low 0.0030

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar